The global enzyme-linked immunosorbent assay (ELISA) testing market size reached USD 2 billion in 2020 and is projected to hit around USD 3.43 billion by 2032, registering a CAGR of 5.60% from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. enzyme-linked immunosorbent assay (ELISA) testing market size was valued at USD 0.46 billion in 2022 and is expected to grow around USD 0.78 billion by 2030, at a CAGR of 6.4% between 2023 and 2032.
North America is Estimated to be the Largest Market for Enzyme-Linked Immunosorbent Assay (ELISA) Testing
The research study covers key prospects and trends of enzyme-linked immunosorbent assay (ELISA) testing products throughout different regions including Europe, North America, Asia-Pacific, Middle East and Africa, and Latin America. Regionally, enzyme-linked immunosorbent assay (ELISA) testing market is dominated by North America due to large investment in research and development and existence of capable scientists. Europe accounted for the second highest share majorly due to high geriatric population. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing investment by major manufacturers, high incidence of infectious disorders, and growing per-capita healthcare expenditure.
An enzyme-linked immunosorbent assay (ELISA), is a procedure that perceives and quantifies antibodies within the blood. ELISA is employed to regulate if an individual has antibodies connected to definite infectious conditions. The advent of cost-effective technologies and automation in laboratories for ELISA assay is anticipated to be the key driver for the worldwide enzyme-linked immunosorbent assay (ELISA) testing market. Furthermore, continuous advances in monoclonal antibodies (mABs) and biomarkers coupled with continuous growth in the drug discovery domain are anticipated to trigger the progress of worldwide ELISA testing industry in the near future. On the contrary, the threat of alternate testing methods using technologies such as multiplex proteomic array platforms may present a challenge to ELISA testing market. However, growing need for accurate and early ailment diagnosis owing to snowballing burden of chronic illnesses across the world along with growing geriatric populace is expected to act as prospects for ELISA testing market in close future.
ELISA testing is an important tool in various applications such as protein quantification, determination of serum antibody concentrations in a virus test, food allergen detection, presence of antigen or antibody in a sample and many more. ELISA technology offers high specificity and sensitivity for analyze detection and quantification and thus is widely used in research applications such as protein quantification during upstream and downstream processing of monoclonal antibodies (mABs), biosimilars development and other protein therapeutics development as well as biomarker selection. Worldwide, the burden of infectious diseases, cancer, HIV infection and other diseases is increasing at a rapid pace. Increasing number of cases of infectious diseases, cancer and other diseases and increasing health awareness has led to increasing demand for accurate and early disease diagnosis tools. Continuous development of innovative and novel product for early and accurate disease diagnosis is projected to open new growth opportunities for major market players in the enzyme-linked immunosorbent assay (ELISA) testing.
| Report Highlights | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.,60% |
| Market Size in 2023 | USD 2.10 Billion |
| Market Size by 2032 | USD 3.43 Billion |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Test, Application, Region |
| Companies Mentioned | Thermo Fisher Scientific, Inc., ALPCO, Bio-Rad Laboratories, Inc., BD, BioMérieux SA, Ortho Clinical Diagnostics, R&D Systems, Inc., ZEUS Scientific, Inc. |
COVID-19 Impact:
The services related to prevention and treatment of non-communicable ailments has been significantly disrupted due to the COVID-19 pandemic, as per a survey published by the World Health Organization (WHO). The main result of the survey is that the healthcare facilities have been partly or entirely disrupted in many regions. Around 53% of the nations surveyed have witnessed partial or total disruption in hypertension treatment, 49% in diabetes treatment and other complications related to diabetes, 42% in treatment of cancer, and 31% in cardiovascular related emergencies. This condition is of significant worry because individuals living with non-communicable ailments are at greater risk of severe COVID-19 related sickness and mortality. Many individuals who need diagnosis for ailments like cardiovascular disease, cancer, tumor, and diabetes have faced difficulties in receiving the services and tests since the COVID-19 pandemic began.
Future of Enzyme-Linked Immunosorbent Assay (ELISA) Testing
The companies operating in the enzyme-linked immunosorbent assay (ELISA) testing market are focusing on developing software’s to regulate the results obtained through ELISA testing. These software’s help in reducing the variability of the ELISA tests.
Sandwich ELISA Test Type Reported Foremost Market Stake in 2022
Sandwich ELISA segment displayed the major share in the worldwide enzyme-linked immunosorbent assay (ELISA) testing market, by test type, in 2022. The improvements carried out in the technology in order to make the test type more efficient is the major reason for high market share of sandwich ELISA. The factors such as multiple benefits over other test types are expected to retain the dominance of continuous flow technology in the near future.
The multiple and portable ELISA is projected grow at the highest CAGR through the forecast time-frame mainly due to technological advancements.
Infectious Diseases Applications of Enzyme-Linked Immunosorbent Assay (ELISA) Testing Dominated the Market Revenue
High incidence of infectious disorders such as Lyme disease, tuberculosis, meningococcal ailments, and salmonella infections are expected to boost the growth of enzyme-linked immunosorbent assay (ELISA) testing market. Cancer applications segment is expected to grow at the highest CAGR over the forecast time-duration.
Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Players
The companies focusing on research and development are expected to lead the global enzyme-linked immunosorbent assay (ELISA) testing market. Leading competitors contending in global enzyme-linked immunosorbent assay (ELISA) testing market are as follows:
In order to well recognize the present status of enzyme-linked immunosorbent assay (ELISA), and policies implemented by the foremost nations, Precedence Research projected the future progress of the enzyme-linked immunosorbent assay (ELISA) testing market. This research report bids quantitative and qualitative insights on enzyme-linked immunosorbent assay (ELISA) testing market and valuation of market size and progress trend for probable market segments.
On November, 2019, ALPCO announced the official launch of its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.
Major Market Segments Covered:
By Test Type
By Application
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
